Symbiotics to Prevent Postoperative Infection in Colorectal Cancer

Change in Incidence of Surgical Site Infection After Resection of Colorectal Cancer Between Patients Receiving a Symbiotic Compound and Patients Receiving a Placebo.

This is a double blind randomized trial in which patients with colorectal cancer undergoing surgery will be selected to receive either a symbiotic formulation or placebo. The researchers will compare incidence of surgical site infection between the study groups.

This is a double blind randomized trial in which patients with colorectal cancer undergoing surgery will be randomly selected to receive either a symbiotic formulation or placebo during the perioperative period. The researchers will compare incidence of surgical site infection, detected by clinical examination and complementary tests (CT scans, X-rays, microbiological and hematological tests) between the study groups.

Inclusion Criteria:

• Adults between 18 and 85 years old;
• Colorectal cancer patients.
• Ability to understand and signing the informed consent

Exclusion Criteria:

• Pregnancy (early diagnosis)
• Reduced intellectual level that could prevent proper understanding of the objectives of the study
• Patients with rectal cancer undergoing neoadjuvant treatment (chemotherapy and radiotherapy)
• Use of products with prebiotic, probiotic and / or symbiotic function or fiber module; by more than 3x a week
• Refusal to participate and / or to sign the Consent Form Free and Clear